Hansson, C. | Search bioRxiv

bioRxiv2025

Tamarixia citricola Hansson and Guerrieri sp. nov. (Hymenoptera: Eulophidae): a new parasitoid of Diaphorina citri Kuwayamava (Hemiptera: Psyllidae) found during a classical biological control program in Cyprus

Asian citrus psyllid, Diaphorina citri, is a major global pest because it is the primary vector of Candidatus Liberibacter spp., the causal agents of huanglongbing (HLB), a lethal citrus disease. Following the detection of D. citri in Cyprus in 2023, the first record of this pest in the European Union, a classical biological control program targeting this pest was initiated in spring 2024 using the parasitoid Tamarixia radiata imported from California, USA. During field surveys in summer 2024, parasitized D. citri nymphs were found in orchards where no T. radiata releases had been made. These findings suggested the possible presence of native or unintentionally introduced parasitoids, or a rapid spread of T. radiata into new areas. To determine the identity of parasitoids associated with D. citri in Cyprus, an integrative approach was adopted combining field observations, molecular analyses of the COI gene, and morphological analyses. Tamarixia radiata recovered from Cyprus field sites matched reference sequences of parasitoids from California. However, other specimens were genetically and morphologically distinct and represented a new species. The new species is described here as Tamarixia citricola Hansson & Guerrieri sp. nov. Taxonomic diagnoses and characters for separating both Tamarixia species associated with D. citri are provided. Results presented here indicate the coexistence of both T. radiata (introduced) and T. citricola (likely autochthonous) in Cyprus citrus orchards. This finding has important implications for future biological control strategies and quarantine measures for D. citri in the Mediterranean basin.

zoology↗

bioRxiv2023

Tr1 cell-mediated protection against autoimmune disease by intranasal administration of a fusion protein targeting cDC1 cells

Curative therapies against autoimmune diseases are lacking. Indeed, most of currently available treatments are only targeting symptoms. We have developed a novel strategy for a therapeutic vaccine against autoimmune diseases based on intranasal administration of a fusion protein tolerogen, which consists of a mutant, enzymatically inactive, cholera toxin A1-subunit genetically fused to disease relevant high affinity peptides and a dimer of D-fragments from protein A. The CTA1R7K-MOG/PLP-DD fusion proteins effectively reduced clinical symptoms in the experimental autoimmune encephalitis (EAE)-model of multiple sclerosis (MS). The treatment induced Tr1 cells, in the draining lymph node, which produced IL-10 and suppressed effector CD4+ T cell responses. This effect was dependent on IL-27 signalling, since treatment was ineffective in bone marrow chimeras lacking IL-27R within their hematopoietic compartment. scRNA-seq of dendritic cells (DC) in draining lymph nodes demonstrated distinct gene transcriptional changes of cDC1, including enhanced lipid metabolic pathways, induced by the tolerogenic fusion protein. Thus, our results with the tolerogenic fusion protein demonstrates the possibility to vaccinate and protect against disease progression by reinstating tolerance in MS and other autoimmune diseases.

immunology↗